BACKGROUND: Omega-3 fatty acid (O3FA) levels and dimensional personality measures have been associated with major depression and the course of depressive illness. We sought to study the utility of O3FA levels and dimensional personality measures as predictors of early improvement with escitalopram. METHODS: Twenty-four participants were enrolled in an open-label trial of escitalopram 10 mg/d for 4 weeks. Baseline erythrocyte O3 levels and dimensional personality assessments were obtained. RESULTS: Using a conservative, intention-to-treat analysis, baseline neuroticism (r = -0.57; P = .007), as measured by the Revised NEO Personality Inventory but not erythrocyte O3 levels, was correlated with improvements on escitalopram. A facet analysis of the neuroticism domain showed the relationship with antidepressant response to be focused on trait anxiety (r = -0.65; P = .002). CONCLUSIONS: Anxiety may have important prognostic implications on subsequent response to selective serotonin reuptake inhibitors, such as escitalopram.
BACKGROUND:Omega-3 fatty acid (O3FA) levels and dimensional personality measures have been associated with major depression and the course of depressive illness. We sought to study the utility of O3FA levels and dimensional personality measures as predictors of early improvement with escitalopram. METHODS: Twenty-four participants were enrolled in an open-label trial of escitalopram 10 mg/d for 4 weeks. Baseline erythrocyte O3 levels and dimensional personality assessments were obtained. RESULTS: Using a conservative, intention-to-treat analysis, baseline neuroticism (r = -0.57; P = .007), as measured by the Revised NEO Personality Inventory but not erythrocyte O3 levels, was correlated with improvements on escitalopram. A facet analysis of the neuroticism domain showed the relationship with antidepressant response to be focused on trait anxiety (r = -0.65; P = .002). CONCLUSIONS:Anxiety may have important prognostic implications on subsequent response to selective serotonin reuptake inhibitors, such as escitalopram.
Authors: Jess G Fiedorowicz; David J Moser; Stephanie M Hynes; Leigh J Beglinger; Susan K Schultz; Vicki L Ellingrod Journal: Psychiatr Genet Date: 2007-02 Impact factor: 2.458
Authors: Marlene P Freeman; Joseph R Hibbeln; Katherine L Wisner; John M Davis; David Mischoulon; Malcolm Peet; Paul E Keck; Lauren B Marangell; Alexandra J Richardson; James Lake; Andrew L Stoll Journal: J Clin Psychiatry Date: 2006-12 Impact factor: 4.384
Authors: Reeta Hakkarainen; Timo Partonen; Jari Haukka; Jarmo Virtamo; Demetrius Albanes; Jouko Lönnqvist Journal: Am J Psychiatry Date: 2004-03 Impact factor: 18.112
Authors: Stefan G Hofmann; Jasper A J Smits; Anu Asnaani; Cassidy A Gutner; Michael W Otto Journal: Pharmacol Biochem Behav Date: 2010-12-04 Impact factor: 3.533
Authors: Katherine M Appleton; Philip D Voyias; Hannah M Sallis; Sarah Dawson; Andrew R Ness; Rachel Churchill; Rachel Perry Journal: Cochrane Database Syst Rev Date: 2021-11-24
Authors: Timothy A Allen; Kate L Harkness; Raymond W Lam; Roumen Milev; Benicio N Frey; Daniel J Mueller; Rudolf Uher; Sidney H Kennedy; Lena C Quilty Journal: Personal Ment Health Date: 2021-05-18